Table 6 Grade 3 to 4 adverse events
Grade 3 to 4, n (%) | Apatinib Based N = 56 | Chemotherapy Based N = 107 | P |  | Apatinib plus Chemotherapy N = 34 | Chemotherapy Alone N = 97 | P |
|---|---|---|---|---|---|---|---|
Hematological events | Â | Â | Â | Â | Â | Â | Â |
Neutropenia | 7 (12.5) | 28 (26.2) | 0.04 | Â | 3 (8.8) | 26 (26.8) | 0.05 |
Anemia | 0 | 6 (5.6) | 0.09 | Â | 0 | 5 (5.2) | 0.33 |
Thrombocytopenia | 3 (5.4) | 4 (3.7) | 0.94 | Â | 1 (2.9) | 4 (4.1) | 1.00 |
Non-hematological events | Â | Â | Â | Â | Â | Â | Â |
Peripheral neuropathy | 0 | 1 (0.9) | 1.00 | Â | 0 | 1 (1.0) | 1.00 |
Nausea/vomiting | 0 | 3 (2.8) | 0.55 | Â | 0 | 2 (2.1) | 1.00 |
Diarrhea | 0 | 0 | - | Â | 0 | 0 | - |
AST/ALT alterations | 2 (3.6) | 6 (5.6) | 0.85 | Â | 0 | 6 (6.2) | 0.34 |
Fatigue | 1 (1.8) | 3 (2.8) | 1.00 | Â | 0 | 0 | - |
Proteinuria | 0 | 0 | - | Â | 0 | 0 | - |
Hypertension | 3 (5.4) | 0 | 0.04 | Â | 2 (5.9) | 0 | 0.07 |
Hand-foot Syndrome | 1 (1.8) | 0 | 0.34 | Â | 1 (2.9) | 0 | 0.26 |
Alopecia | 0 | 1 (0.9) | 1.00 | Â | 0 | 1 (1.0) | 1.00 |